Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
arcticnovartis

  • There is currently no evidence-based treatment for the smallest babies with malaria
  • The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg
  • The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review

Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from the

/by
Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
arcticnovartis

  • Transaction reinforces company’s strategic focus on developing next-generation treatment options for patients living with cancer
  • Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet need
  • Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications

Basel, May 2, 2024 – Novartis today announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage bio

/by